Â鶹ӳ»­

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at Â鶹ӳ»­ MD Anderson Cancer Center...

Â鶹ӳ»­ MD Anderson Cancer Center today was awarded nearly $8 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of faculty recruitment as well as lung and colorectal cancer screening and early detection programs to address cancer incidence rates across Texas.

¡°CPRIT¡¯s continued support is essential for progress in our mission to end cancer, and we appreciate this important funding...